Healthcare and logistics company the Mayne Pharma Group (ASX:MYX) reports its adjusted net profit after tax fell 33 per cent on last year’s to $60.3 million from 90.2 million.
It’s revenue is down 7 per cent on the prior corresponding period to $530.3 million from $572.6 million last year.
It’s reported EBITDA is $116.8 million, that’s 48 per cent down from last year’s $224.2 million.
The CEO says the Company has invested $44 million in research and development, and filed eight products with the FDA.
No dividend has been declared for financial year 2018.
Shares in Mayne Pharma Group (ASX:MYX) are trading 4.29 per cent higher to $1.09.